Workflow
mRNA Vaccine Maker Moderna Lowers R&D Spending, Tightens Sales Forecast
ModernaModerna(US:MRNA) Benzinga·2025-11-07 01:29

Moderna Inc. (NASDAQ:MRNA) reported a third-quarter loss of 51 cents, beating the expected loss of 2.02,aturnaroundfromanincomeof3centsayearago.MRNAstockisracingaheadofthepack.GetthecompleteanalysishereTheCOVID19vaccinemakerreportedquarterlysalesof2.02, a turnaround from an income of 3 cents a year ago.MRNA stock is racing ahead of the pack. Get the complete analysis hereThe COVID-19 vaccine maker reported quarterly sales of 1.02 billion, topping the expected 886.54million.Salesdeclined45886.54 million.Sales declined 45% to 1.9 billion from a year ago, primarily due to a $847 million, or 47%, decrease in net product sales, as COVID vaccine sales decreased.In the U.S., lower sal ...